The impact of making vaccines thermostable in Niger's vaccine supply chain

Bruce Lee, Brigid E. Cakouros, Tina Marie Assi, Diana L. Connor, Joel Welling, Souleymane Kone, Ali Djibo, Angela R. Wateska, Lionel Pierre, Shawn T. Brown

Research output: Contribution to journalArticle

Abstract

Objective: Determine the effects on the vaccine cold chain of making different types of World Health Organization (WHO) Expanded Program on Immunizations (EPI) vaccines thermostable. Methods: Utilizing a detailed computational, discrete-event simulation model of the Niger vaccine supply chain, we simulated the impact of making different combinations of the six current EPI vaccines thermostable. Findings: Making any EPI vaccine thermostable relieved existing supply chain bottlenecks (especially at the lowest levels), increased vaccine availability of all EPI vaccines, and decreased cold storage and transport capacity utilization. By far, the most substantial impact came from making the pentavalent vaccine thermostable, increasing its own vaccine availability from 87% to 97% and the vaccine availabilities of all other remaining non-thermostable EPI vaccines to over 93%. By contrast, making each of the other vaccines thermostable had considerably less effect on the remaining vaccines, failing to increase the vaccine availabilities of other vaccines to more than 89%. Making tetanus toxoid vaccine along with the pentavalent thermostable further increased the vaccine availability of all EPI vaccines by at least 1-2%. Conclusion: Our study shows the potential benefits of making any of Niger's EPI vaccines thermostable and therefore supports further development of thermostable vaccines. Eliminating the need for refrigerators and freezers should not necessarily be the only benefit and goal of vaccine thermostability. Rather, making even a single vaccine (or some subset of the vaccines) thermostable could free up significant cold storage space for other vaccines, and thereby help alleviate supply chain bottlenecks that occur throughout the world.

Original languageEnglish (US)
Pages (from-to)5637-5643
Number of pages7
JournalVaccine
Volume30
Issue number38
DOIs
StatePublished - Aug 17 2012
Externally publishedYes

Fingerprint

Niger
supply chain
Vaccines
vaccines
Immunization Programs
immunization
Tetanus Toxoid
cold storage

Keywords

  • Supply chain
  • Thermostable
  • Vaccines

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Lee, B., Cakouros, B. E., Assi, T. M., Connor, D. L., Welling, J., Kone, S., ... Brown, S. T. (2012). The impact of making vaccines thermostable in Niger's vaccine supply chain. Vaccine, 30(38), 5637-5643. https://doi.org/10.1016/j.vaccine.2012.06.087

The impact of making vaccines thermostable in Niger's vaccine supply chain. / Lee, Bruce; Cakouros, Brigid E.; Assi, Tina Marie; Connor, Diana L.; Welling, Joel; Kone, Souleymane; Djibo, Ali; Wateska, Angela R.; Pierre, Lionel; Brown, Shawn T.

In: Vaccine, Vol. 30, No. 38, 17.08.2012, p. 5637-5643.

Research output: Contribution to journalArticle

Lee, B, Cakouros, BE, Assi, TM, Connor, DL, Welling, J, Kone, S, Djibo, A, Wateska, AR, Pierre, L & Brown, ST 2012, 'The impact of making vaccines thermostable in Niger's vaccine supply chain', Vaccine, vol. 30, no. 38, pp. 5637-5643. https://doi.org/10.1016/j.vaccine.2012.06.087
Lee B, Cakouros BE, Assi TM, Connor DL, Welling J, Kone S et al. The impact of making vaccines thermostable in Niger's vaccine supply chain. Vaccine. 2012 Aug 17;30(38):5637-5643. https://doi.org/10.1016/j.vaccine.2012.06.087
Lee, Bruce ; Cakouros, Brigid E. ; Assi, Tina Marie ; Connor, Diana L. ; Welling, Joel ; Kone, Souleymane ; Djibo, Ali ; Wateska, Angela R. ; Pierre, Lionel ; Brown, Shawn T. / The impact of making vaccines thermostable in Niger's vaccine supply chain. In: Vaccine. 2012 ; Vol. 30, No. 38. pp. 5637-5643.
@article{9fb7add8ad274989baa86a1daecbb50b,
title = "The impact of making vaccines thermostable in Niger's vaccine supply chain",
abstract = "Objective: Determine the effects on the vaccine cold chain of making different types of World Health Organization (WHO) Expanded Program on Immunizations (EPI) vaccines thermostable. Methods: Utilizing a detailed computational, discrete-event simulation model of the Niger vaccine supply chain, we simulated the impact of making different combinations of the six current EPI vaccines thermostable. Findings: Making any EPI vaccine thermostable relieved existing supply chain bottlenecks (especially at the lowest levels), increased vaccine availability of all EPI vaccines, and decreased cold storage and transport capacity utilization. By far, the most substantial impact came from making the pentavalent vaccine thermostable, increasing its own vaccine availability from 87{\%} to 97{\%} and the vaccine availabilities of all other remaining non-thermostable EPI vaccines to over 93{\%}. By contrast, making each of the other vaccines thermostable had considerably less effect on the remaining vaccines, failing to increase the vaccine availabilities of other vaccines to more than 89{\%}. Making tetanus toxoid vaccine along with the pentavalent thermostable further increased the vaccine availability of all EPI vaccines by at least 1-2{\%}. Conclusion: Our study shows the potential benefits of making any of Niger's EPI vaccines thermostable and therefore supports further development of thermostable vaccines. Eliminating the need for refrigerators and freezers should not necessarily be the only benefit and goal of vaccine thermostability. Rather, making even a single vaccine (or some subset of the vaccines) thermostable could free up significant cold storage space for other vaccines, and thereby help alleviate supply chain bottlenecks that occur throughout the world.",
keywords = "Supply chain, Thermostable, Vaccines",
author = "Bruce Lee and Cakouros, {Brigid E.} and Assi, {Tina Marie} and Connor, {Diana L.} and Joel Welling and Souleymane Kone and Ali Djibo and Wateska, {Angela R.} and Lionel Pierre and Brown, {Shawn T.}",
year = "2012",
month = "8",
day = "17",
doi = "10.1016/j.vaccine.2012.06.087",
language = "English (US)",
volume = "30",
pages = "5637--5643",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "38",

}

TY - JOUR

T1 - The impact of making vaccines thermostable in Niger's vaccine supply chain

AU - Lee, Bruce

AU - Cakouros, Brigid E.

AU - Assi, Tina Marie

AU - Connor, Diana L.

AU - Welling, Joel

AU - Kone, Souleymane

AU - Djibo, Ali

AU - Wateska, Angela R.

AU - Pierre, Lionel

AU - Brown, Shawn T.

PY - 2012/8/17

Y1 - 2012/8/17

N2 - Objective: Determine the effects on the vaccine cold chain of making different types of World Health Organization (WHO) Expanded Program on Immunizations (EPI) vaccines thermostable. Methods: Utilizing a detailed computational, discrete-event simulation model of the Niger vaccine supply chain, we simulated the impact of making different combinations of the six current EPI vaccines thermostable. Findings: Making any EPI vaccine thermostable relieved existing supply chain bottlenecks (especially at the lowest levels), increased vaccine availability of all EPI vaccines, and decreased cold storage and transport capacity utilization. By far, the most substantial impact came from making the pentavalent vaccine thermostable, increasing its own vaccine availability from 87% to 97% and the vaccine availabilities of all other remaining non-thermostable EPI vaccines to over 93%. By contrast, making each of the other vaccines thermostable had considerably less effect on the remaining vaccines, failing to increase the vaccine availabilities of other vaccines to more than 89%. Making tetanus toxoid vaccine along with the pentavalent thermostable further increased the vaccine availability of all EPI vaccines by at least 1-2%. Conclusion: Our study shows the potential benefits of making any of Niger's EPI vaccines thermostable and therefore supports further development of thermostable vaccines. Eliminating the need for refrigerators and freezers should not necessarily be the only benefit and goal of vaccine thermostability. Rather, making even a single vaccine (or some subset of the vaccines) thermostable could free up significant cold storage space for other vaccines, and thereby help alleviate supply chain bottlenecks that occur throughout the world.

AB - Objective: Determine the effects on the vaccine cold chain of making different types of World Health Organization (WHO) Expanded Program on Immunizations (EPI) vaccines thermostable. Methods: Utilizing a detailed computational, discrete-event simulation model of the Niger vaccine supply chain, we simulated the impact of making different combinations of the six current EPI vaccines thermostable. Findings: Making any EPI vaccine thermostable relieved existing supply chain bottlenecks (especially at the lowest levels), increased vaccine availability of all EPI vaccines, and decreased cold storage and transport capacity utilization. By far, the most substantial impact came from making the pentavalent vaccine thermostable, increasing its own vaccine availability from 87% to 97% and the vaccine availabilities of all other remaining non-thermostable EPI vaccines to over 93%. By contrast, making each of the other vaccines thermostable had considerably less effect on the remaining vaccines, failing to increase the vaccine availabilities of other vaccines to more than 89%. Making tetanus toxoid vaccine along with the pentavalent thermostable further increased the vaccine availability of all EPI vaccines by at least 1-2%. Conclusion: Our study shows the potential benefits of making any of Niger's EPI vaccines thermostable and therefore supports further development of thermostable vaccines. Eliminating the need for refrigerators and freezers should not necessarily be the only benefit and goal of vaccine thermostability. Rather, making even a single vaccine (or some subset of the vaccines) thermostable could free up significant cold storage space for other vaccines, and thereby help alleviate supply chain bottlenecks that occur throughout the world.

KW - Supply chain

KW - Thermostable

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84864742639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864742639&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.06.087

DO - 10.1016/j.vaccine.2012.06.087

M3 - Article

C2 - 22789507

AN - SCOPUS:84864742639

VL - 30

SP - 5637

EP - 5643

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 38

ER -